ArticleMedical oncology (Northwood, London, England)2024

Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.

Seiichi Okabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.